With only $2.2M cash and a $2.8M annual operating burn rate, NewcelX will need additional financing within the next 12 months. The recent $1.35M placement and $25M ELOC provide a bridge but signal ongoing dilution risk. Monitor for IND-enabling milestones on NCEL-101 as the primary catalyst; without them, the stock remains a high-risk micro-cap with limited runway.
Price Chart
Executive Summary
NewcelX reported FY2025 results with a net loss of $8.3M (including $5.7M non-cash finance expenses) and cash of $2.2M. The company highlighted progress on its lead T1D therapy NCEL-101 and a recent $3.4M financing, but the financials show a widening operating loss and no revenue. The stock is a micro-cap with no analyst bullish coverage and a history of high volatility.
Key Financial Metrics
Key Facts
- Net loss for FY2025 was $8.3M, compared to $7.2M in FY2024
- Operating loss widened to $2.6M from $2.1M in FY2024
- Cash and cash equivalents were $2.2M as of Dec 31, 2025
- Net cash used in operations was $2.8M in FY2025
- Company completed a $1.35M private placement in April 2026 with up to $2M in warrant proceeds
- No revenue reported for FY2025 or FY2024
- Basic and diluted loss per share was $(2.16) vs $(2.43) in FY2024
- Company maintains access to a $25M Equity Line of Credit
Financial Impact
Net loss of $8.3M with $2.2M cash on hand; operating cash burn of $2.8M annually
Risk Factors
- Cash runway of less than 12 months at current burn rate
- No revenue and no approved products — pre-revenue clinical stage
- Dilution risk from $25M Equity Line of Credit and warrant exercises
- Going concern risk flagged in forward-looking statements
- Nasdaq listing compliance risk for a $16M market cap company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284829 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | EFFECT | $2.86 $3.08 | ▼ −7.52% | ▼ −8.19% | $2.55 (+10.84%) |
Sep 18, 2026 5w ago | 6-K | $2.97 $2.92 | ▲ +1.68% | ▲ +0.66% | $2.55 (+14.14%) |
Aug 27, 2026 8w ago | EFFECT | $3.42 $3.35 | ▲ +2.05% | ▲ +1.28% | $2.55 (+25.44%) |
Jul 31, 2026 12w ago | 6-K | $3.49 $3.31 | ▼ −5.16% | ▼ −8.67% | $2.55 (−26.93%) |
Jul 15, 2026 14w ago | 6-K | $3.93 $3.65 | ▼ −7.12% | ▼ −6.14% | $2.55 (−35.11%) |
Jul 8, 2026 15w ago | 6-K | $4.23 $3.98 | ▼ −5.91% | ▼ −6.77% | $2.55 (−39.72%) |
Jul 1, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.55 (−33.77%) |
Jun 30, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.55 (−33.77%) |
Jun 18, 2026 18w ago | EFFECT | $3.31 $3.55 | ▼ −7.25% | ▼ −8.92% | $2.55 (+22.96%) |
Jun 5, 2026 20w ago | 6-K | $3.24 $3.20 | ▼ −1.23% | ▼ −3.35% | $2.55 (−21.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers